The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

被引：0
|
作者：
Uzma Khan
Helena Huerga
Aamir J. Khan
Carole D. Mitnick
Catherine Hewison
Francis Varaine
Mathieu Bastard
Michael Rich
Molly F. Franke
Sidney Atwood
Palwasha Y. Khan
Kwonjune J. Seung
机构：
[1] Interactive Research and Development (IRD),Field Epidemiology Department
[2] Epicentre,Department of Global Health and Social Medicine
[3] Interactive Research and Development (IRD) Global,Medical Department
[4] Harvard Medical School,Division of Global Health Equity
[5] Médecins Sans Frontières,undefined
[6] Partners In Health,undefined
[7] Brigham and Women’s Hospital,undefined
来源：
BMC Infectious Diseases | / 19卷
关键词：
MDR-TB; Bedaquiline; Delamanid; Safety; Efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Treatment and management of MDR-TB in Latvia
    Leimane, Vaira
    BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2007, 85 (05) : 393 - 394
  • [32] Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
    Hafkin, Jeffrey
    Hittel, Norbert
    Martin, Alexandra
    Gupta, Rajesh
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (01)
  • [33] Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006
    Masjedi, M. R.
    Tabarsi, P.
    Chitsaz, E.
    Baghaei, P.
    Mirsaeidi, M.
    Amiri, M. V.
    Farnia, P.
    Javanmard, P.
    Mansouri, D.
    Velayati, A. A.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2008, 12 (07) : 750 - 755
  • [34] Tolerance to chemotherapy regimens with bedaquiline in adolescents with MDR/XDR pulmonary TB
    Piskunova, Olga
    Panova, Ludmila
    Ovsyankina, Elena
    Krushinskaya, Ekaterina
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [35] Impact of prompt MDR-TB treatment initiation: significant reduction of MDR-TB mortality rate in Rwanda
    Ngabonziza, J. C. S.
    Habimana, M. Y.
    Migambi, P.
    Mazarati, J. B.
    de Jong, B. C.
    Torrea, G.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 214 - 215
  • [36] Impact of Prior TB Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for MDR/RR-TB
    Mikiashvili, L.
    Kempker, R. R.
    Chakhaia, T. S.
    Bablishvili, N.
    Avaliani, Z.
    Lomtadze, N.
    Schechter, M. C.
    Kipiani, M.
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (04) : 1043 - 1052
  • [37] Preliminary results of 24-36 weeks of bedaquiline, delamanid, clofazimine and pyrazinamide for the treatment of MDR/RR-TB
    Liu, Yidian
    Sha, Wei
    Wang, Hua
    Gong, Weiliang
    Zeng, Zhong
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [38] Preventive treatment for MDR-TB exposure in households
    Malik, A. A.
    Hussain, H.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2022, 26 (05) : 466 - 467
  • [39] Clinical experience of clofazimine in the treatment of MDR-TB
    Yoo, Jung-Wan
    Lyu, Jiwon
    Lee, Sang Do
    Kim, Woo Sung
    Kim, Dong Soon
    Shim, Tae Sun
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [40] Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)
    Liu, Yongge
    Matsumoto, Makoto
    Ishida, Hidekaza
    Ohguro, Kinue
    Yoshitake, Masuhiro
    Gupta, Rajesh
    Geiter, Lawrence
    Hafkin, Jeffrey
    TUBERCULOSIS, 2018, 111 : 20 - 30
12345